GRYPHON BIO INC — Department of Health and Human Services SBIR Phase I: 106

Description

ABSTRACT Traumatic brain injury (TBI) is a leading cause of mortality and morbidity in the US, with over two million new patients each year and no FDA-approved therapeutics. TBI induces an early, high concentration wave of cytotoxic glutamate into synapses that exceeds the buffering capacity of astroglial glutamate transporters (e.g. GLT-1), causing injury and death of brain cells. Under these neurotrauma conditions, the calpain- generated, 38 kDa core breakdown product of glial fibrillary acidic protein (GBDP) was released from injured astrocytes within hours to days post-injury. In parallel, other protein “debris” are released from neuronal cell bodies (ubiquitin C terminal hydrolase 1 /UCH-L1) and injured axons (neurofilament-heavy /pNF-H and light /NF-L, Tau and phosphorylated Tau /p-Tau). In fact, our most recent clinical data from TRACK-TBI and CENTER-TBI multicenter consortium studies showed that GFAP/GDBPs are the most the abundant protein debris released into the circulation after TBI. Significantly, we and others discovered that GBDPs are prone to form protein aggregates that are neurotoxic when externalized. Grus and coworkers reported that anti-GFAP antibodies have neuroprotective effects on cultured neuro-retinal cells and on retinal ganglion cells in organotypic culture under stress. Similarly, GBDP active immunization was neuroprotective in a mouse model of TBI, including attenuation of GBDP levels, reduction of key neuropathological biomarkers of TBI, and improvement of neurofunctional outcomes. Therefore, our central hypothesis is that passive immunotherapy with effector-competent IgG monoclonal antibodies (mAbs) against GBDP will accelerate brain repair and improve cognition and other outcome measures in TBI patients. Our proposed mechanism of action is the beneficial opsonization of neurotoxic GBDP debris by anti-GBDP mAb (IgG), followed by accelerated phagocytosis by activated FcγR+ phagocytes. Our content of use is TBI patients with a significant injury, as defined by moderate to severe TBI patients with initial GCS of 6-12 and elevated levels of selected acute temporal predictive biomarkers for targeted enrollment. Our proposed route of administration is intravenous multiday infusion of anti-GBDP mAbs to maximize brain exposure, with subacute temporal pharmacodynamic (PD) biomarkers (such as GBDP, NFL, Tau and p-Tau) to track treatment response and adjust dosing. In this project, we leverage our synergistic expertise to test our hypothesis with (Phase I) proof-of-concept in vitro and cell-based studies prior to (Phase II) in vivo dose-ranging and efficacy studies to prioritize and characterize our lead anti-GBDP mAb immunotherapy candidates. Our preliminary preclinical studies now show that pre-injury, active immunization with GDBP AND post- injury passive immunotherapy with anti-GBDP mAbs are safe and beneficial in TBI mice. Moreover, we show how PD biomarkers might be employed to track treatment response and adjust dosing for successful translation from the laboratory to the clinic and to aid in meaningful benefit–risk decision-making.Narrative Traumatic brain injury (TBI) is a leading cause of mortality and morbidity around the world with approximately two million new patients each year in the US alone and no approved medicines. We hypothesize that immunotherapy with monoclonal antibodies (mAbs) will accelerate nature’s own mechanisms for devouring some of the most abundant and harmful brain cell debris that is released into the extracellular fluid of the brain during TBI. If successful, then mAb immunotherapy will be the first precision medicine to accelerate brain repair and improve cognition for TBI patients.